693774-26-4

Usage

Uses

Used in Pharmaceutical Synthesis:
3-Bromophenyl cyclopropyl ketone is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to undergo multiple chemical reactions, contributing to the development of new and improved medications.
Used in Organic Compound Synthesis:
In the field of organic chemistry, 3-Bromophenyl cyclopropyl ketone serves as a valuable building block for creating more complex molecules, facilitating the advancement of research and innovation in organic compound development.
Safety Precautions:
It is crucial to handle 3-Bromophenyl cyclopropyl ketone with care, as it is classified as a hazardous chemical. Exposure may result in skin, eye, and respiratory system irritation, necessitating proper safety measures during its use and storage.

InChI:InChI=1/C10H9BrO/c11-9-3-1-2-8(6-9)10(12)7-4-5-7/h1-3,6-7H,4-5H2

Upstream product

• 925430-09-7 tricyclopropylbismuthane 
• 591-18-4 1-Bromo-3-iodobenzene 
• 201230-82-2 carbon monoxide 
• 108-36-1 1,3-dibromobenzene 
• 147356-78-3 cyclopropanecarboxylic acid N-methoxy-N-methylamide 
• 79134-92-2 (3-bromophenyl)(cyclopropyl)methanol 
• 3132-99-8 m-bromobenzoic aldehyde 
• 1711-09-7 3-bromobenzoyl chloride 

Downstream Products

• 1372806-11-5 5-(3-bromophenyl)-5-cyclopropyl-3-methylimidazolidine-2,4-dione 
• 1372806-26-2 5-(3-bromophenyl)-5-cyclopropyl-3-methyl-2-thioxoimidazolidin-4-one 
• 1049686-36-3 5-(3-bromophenyl)-5-cyclopropyl-2-imino-3-methylimidazolidin-4-one 
• 1049669-09-1 C₁₁H₁₂BrNO₂ 
• 1370656-89-5 C₁₂H₁₄BrNO₂ 
• 1370656-90-8 C₁₃H₁₃BrN₂OS 
• 1049639-30-6 C₁₃H₁₄BrN₃O 
• 887911-70-8 C₁₉H₁₈ClN₃O 
• 887911-83-3 C₁₉H₁₇Cl₂N₃O 
• 887911-67-3 5-cyclopropyl-2-imino-5-(3-(3-methoxyphenyl)phenyl)-3-methylimidazolidin-4-one 
• 887911-65-1 C₂₀H₁₈N₄O 
• 887911-56-0 C₁₈H₁₈N₄O 
• 887913-84-0 C₁₉H₂₀N₄O₂ 
• 887910-96-5 C₁₉H₁₇N₅O 

Relevant academic research and scientific papers

SMALL MOLECULE MODULATORS OF IL-17

The present invention relates to a compound according to formula I and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to, to said compounds for use in therapy, to pharmaceutical compositions comprising said

AMINO-ACID ANILIDES AS SMALL MOLECULE MODULATORS OF IL-17

The present invention relates to a compound according to formula I (I) and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

Silylium-Ion-Promoted (5+1) Cycloaddition of Aryl-Substituted Vinylcyclopropanes and Hydrosilanes Involving Aryl Migration

A transition-metal-free (5+1) cycloaddition of aryl-substituted vinylcyclopropanes (VCPs) and hydrosilanes to afford silacyclohexanes is reported. Catalytic amounts of the trityl cation initiate the reaction by hydride abstraction from the hydrosilane, and further progress of the reaction is maintained by self-regeneration of the silylium ions. The new reaction involves a [1,2] migration of an aryl group, eventually furnishing 4- rather than 3-aryl-substituted silacyclohexane derivatives as major products. Various control experiments and quantum-chemical calculations support a mechanistic picture where a silylium ion intramolecularly stabilized by a cyclopropane ring can either undergo a kinetically favored concerted [1,2] aryl migration/ring expansion or engage in a cyclopropane-to-cyclopropane rearrangement.

Palladium-Catalyzed Carbonylative Cross-Coupling Reaction between Aryl(Heteroaryl) Iodides and Tricyclopropylbismuth: Expedient Access to Aryl Cyclopropylketones

The carbonylative cross-coupling reaction between aryl and heteroaryl iodides and tricyclopropylbismuth is reported. The reaction is catalyzed by (SIPr)Pd(allyl)Cl, a NHC-palladium(II) catalyst, operates under 1 atm of carbon monoxide and tolerates a wide range of functional groups. The use of lithium chloride was found to provide higher yields of the desired aryl cyclopropylketones. The conditions were also applied to the carbonylative cross-coupling of an iodoalkene to afford the corresponding alkenyl cyclopropylketone.

Structure based design of iminohydantoin BACE1 inhibitors: Identification of an orally available, centrally active BACE1 inhibitor

From an initial lead 1, a structure-based design approach led to identification of a novel, high-affinity iminohydantoin BACE1 inhibitor that lowers CNS-derived Aβ following oral administration to rats. Herein we report SAR development in the S3 and F′ subsites of BACE1 for this series, the synthetic approaches employed in this effort, and in vivo data for the optimized compound.